Turning Point Therapeutics, Inc. Common Stock
TPTX
TPTX was delisted on the 16th of August, 2022.
190 hedge funds and large institutions have $2.98B invested in Turning Point Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 69 increasing their positions, 67 reducing their positions, and 20 closing their positions.
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
3% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 67
0% more funds holding
Funds holding: 190 → 190 (0)
17% less capital invested
Capital invested by funds: $3.58B → $2.98B (-$599M)
44% less call options, than puts
Call options by funds: $684K | Put options by funds: $1.23M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$37.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$27.9M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$25.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$16.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$64.8M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$36.3M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$31.2M |
| 4 |
Jennison Associates
New York
|
-$21.2M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$13.9M |
TPTX Hedge Fund Activity: Q3 2021 in Review
190 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q3 2021, worth a combined $2.98B — down 17% from $3.58B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new TPTX positions and 20 closed out — a net gain of 3 holders — while 69 added to existing stakes and 67 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $37.4M. The largest seller was Fidelity Investments, cutting an estimated $64.8M.
- 190 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $2.98B of Turning Point Therapeutics, Inc. Common Stock stock for Q3 2021, down 17% quarter-over-quarter.
- 23 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q3 2021 and 20 closed out, a net change of +3 holders.
- The largest Turning Point Therapeutics, Inc. Common Stock buyer in Q3 2021 was Boxer Capital, an estimated $37.4M added.
- The largest Turning Point Therapeutics, Inc. Common Stock seller in Q3 2021 was Fidelity Investments, an estimated $64.8M sold.
Based on aggregated 13F filings for Q3 2021.